Shape the future of psychedelic therapies at the Pathways to Access Summit in June 2024

2024 stands as a pivotal year for psychedelic medicine, with important ongoing developments such as potential FDA approval of MDMA-assisted therapy, PsyPal: the first EU-funded study into psychedelic-assisted therapy, and the seminal multi-stakeholder workshop on psychedelics hosted by the European Medicines Agency (EMA).
Building on these developments, The Pathways to Access Summit on June 5th 2024 will expand the conversation by incorporating global perspectives and deepening the focus on industry viewpoints. Key stakeholders from government, industry, non-profits, and regulatory bodies, including the EMA, Janssen, Cybin, Lykos, Drug Science, and PAREA, will propel these discussions forward.
Learn more: icpr-conference.com/paths
Moreover, for the first time, attendees can actively participate and shape the agenda through our Unconferencing Segment: Open Space Sessions. This interactive approach ensures that Paths not only addresses the predefined topics but also the pressing issues brought forth by participants, tapping into the collective expertise of all attendees.
Are you a researcher, drug developer, regulator, student, or therapist who wants to shape the future of psychedelic therapies in Europe?
Join the Pathways to Access Summit. You can find the full programme here: open-foundation-icpr.s3.amazo...

[@portierpsy]

Great initiative guys. We can't make it to ICPR this year, but glad to see you guys helping to navigate this maze ~ hopefully to get Europe to lead, not lag, in the realm of psychedelic medicine.